Thor Halfdanarson, Professor of Oncology at Mayo Clinic School of Medicine, shared a post on X:
“I just love practical NET studies, even if small. Such as this one from the Moffitt Team (Jon Strosberg who I have yet to find on X, Ghassan El-Haddad (who I can only find on Strava but we don’t talk NENs over there, only bicycles), Taymeyah Al-Toubah, Menna Haider and Jaime Montilla-Soler.
SSTR expression in poorly differentiated extrapulmonary neuroendocrine carcinoma (epNECs) is NOT common. 13% in this PET study. Quite a bit higher in other studies but in this nicely done study, uniform avidity is uncommon.
My take:
- Stop ordering routine SSTR (DOTATATE) PET in these patients. It’s a waste of money and resources (spend it on molecular/NGS studies instead).
- The SSTR is not yet (and may never be) a suitable target for most patients with epNECs given the heterogeneous expression. But to know that, we need more research.
- The only way to learn more about the potential usefulness of SSTR as a target in epNECs is to participate in trials. If there is a trial available, consider offering/referring for that.”
Title: Somatostatin Receptor Expression on [68Ga]Ga-DOTATATE PET Among Patients with Poorly Differentiated Extrapulmonary Neuroendocrine Carcinomas: A Prospective Study
Authors: Jonathan R. Strosberg, Taymeyah Al-Toubah, Mintallah Haider, Ghassan El-Haddad, Jaime Montilla-Soler
Read the Full Article.
Other Articles Featuring Thor Halfdanarson On OncoDaily.